Literature DB >> 31970170

Prognostic factors for overall survival in prostate cancer patients with different site-specific visceral metastases: A study of 1358 patients.

Peng-Fei Cui1, Xiao-Feng Cong1, Feng Gao1, Jia-Xin Yin1, Zi-Ru Niu1, Song-Chen Zhao1, Zi-Ling Liu2.   

Abstract

BACKGROUND: Distant metastasis, particularly visceral metastasis (VM), represents an important negative prognostic factor for prostate cancer (PCa) patients. However, due to the lower rate of occurrence of VM, studies on these patients are relatively rare. Consequently, studies focusing on prognostic factors associated with PCa patients with VM are highly desirable. AIM: To investigate the prognostic factors for overall survival (OS) in PCa patients with lung, brain, and liver metastases, respectively, and evaluate the impact of site-specific and number-specific VM on OS.
METHODS: Data on PCa patients with VM were extracted from the Surveillance, Epidemiology, and End Results database between 2010 and 2015. Univariate and multivariate Cox regression analyses were used to analyze the association between clinicopathological characteristics and survival of patients with different site-specific VM. Kaplan-Meier analyses and Log-rank tests were performed to analyze the differences among the groups.
RESULTS: A total of 1358 PCa patients with site-specific VM were identified from 2010 to 2015. Older age (> 70 years) (P < 0.001), higher stage (T3/T4) (P = 0.004), and higher Gleason score (> 8) (P < 0.001) were found to be significant independent prognostic factors associated with poor OS in PCa patients with lung metastases. Higher stage (T3/T4) (P = 0.047) was noted to be the only independent risk factor affecting OS in PCa patients with brain metastases. Older age (> 70 years) (P = 0.010) and higher Gleason score (> 8) (P = 0.001) were associated with shorter OS in PCa patients with liver metastases. PCa patients with isolated lung metastases exhibited significantly better survival outcomes compared with PCa patients with other single sites of VM (P < 0.001). PCa patients with a single site of VM exhibited a superior OS compared with PCa patients with multiple sites of VM (P < 0.001).
CONCLUSION: This is the first Surveillance, Epidemiology, and End Results-based study to determine prognostic factors affecting OS in PCa patients with different site-specific VM. Clinical assessments of these crucial prognostic factors become necessary before establishing a treatment strategy for these patients with metastatic PCa. ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.

Entities:  

Keywords:  Overall survival; Prognostic factors; Prostate cancer; Visceral metastases

Year:  2020        PMID: 31970170      PMCID: PMC6962083          DOI: 10.12998/wjcc.v8.i1.54

Source DB:  PubMed          Journal:  World J Clin Cases        ISSN: 2307-8960            Impact factor:   1.337


  32 in total

1.  Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer.

Authors:  Andrew J Armstrong; Elizabeth Garrett-Mayer; Ronald de Wit; Ian Tannock; Mario Eisenberger
Journal:  Clin Cancer Res       Date:  2009-12-15       Impact factor: 12.531

2.  The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer.

Authors:  Gregory R Pond; Guru Sonpavde; Ronald de Wit; Mario A Eisenberger; Ian F Tannock; Andrew J Armstrong
Journal:  Eur Urol       Date:  2013-10-05       Impact factor: 20.096

3.  Increase in Prostate Cancer Distant Metastases at Diagnosis in the United States.

Authors:  Jim C Hu; Paul Nguyen; Jialin Mao; Joshua Halpern; Jonathan Shoag; Jason D Wright; Art Sedrakyan
Journal:  JAMA Oncol       Date:  2017-05-01       Impact factor: 31.777

Review 4.  The changing face of prostate cancer.

Authors:  Matthew R Cooperberg; Judd W Moul; Peter R Carroll
Journal:  J Clin Oncol       Date:  2005-11-10       Impact factor: 44.544

5.  Liver metastases in prostate carcinoma: clinical characteristics and outcome.

Authors:  Damien Pouessel; Blandine Gallet; Frédéric Bibeau; Christophe Avancès; François Iborra; Pierre Sénesse; Stéphane Culine
Journal:  BJU Int       Date:  2006-11-28       Impact factor: 5.588

6.  Prostate cancer collaborative stage data items--their definitions, quality, usage, and clinical implications: a review of SEER data for 2004-2010.

Authors:  Maria J Schymura; Leon Sun; Antoinette Percy-Laurry
Journal:  Cancer       Date:  2014-12-01       Impact factor: 6.860

7.  Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer.

Authors:  Susan Halabi; William Kevin Kelly; Hua Ma; Haojin Zhou; Nicole C Solomon; Karim Fizazi; Catherine M Tangen; Mark Rosenthal; Daniel P Petrylak; Maha Hussain; Nicholas J Vogelzang; Ian M Thompson; Kim N Chi; Johann de Bono; Andrew J Armstrong; Mario A Eisenberger; Abderrahim Fandi; Shaoyi Li; John C Araujo; Christopher J Logothetis; David I Quinn; Michael J Morris; Celestia S Higano; Ian F Tannock; Eric J Small
Journal:  J Clin Oncol       Date:  2016-03-07       Impact factor: 44.544

Review 8.  Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology.

Authors:  Jean-Pierre Droz; Matti Aapro; Lodovico Balducci; Helen Boyle; Thomas Van den Broeck; Paul Cathcart; Louise Dickinson; Eleni Efstathiou; Mark Emberton; John M Fitzpatrick; Axel Heidenreich; Simon Hughes; Steven Joniau; Michael Kattan; Nicolas Mottet; Stéphane Oudard; Heather Payne; Fred Saad; Toru Sugihara
Journal:  Lancet Oncol       Date:  2014-08       Impact factor: 41.316

9.  Distribution of metastatic sites in patients with prostate cancer: A population-based analysis.

Authors:  Giorgio Gandaglia; Firas Abdollah; Jonas Schiffmann; Vincent Trudeau; Shahrokh F Shariat; Simon P Kim; Paul Perrotte; Francesco Montorsi; Alberto Briganti; Quoc-Dien Trinh; Pierre I Karakiewicz; Maxine Sun
Journal:  Prostate       Date:  2013-10-16       Impact factor: 4.104

10.  Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer.

Authors:  O B Goodman; T W Flaig; A Molina; P F A Mulders; K Fizazi; H Suttmann; J Li; T Kheoh; J S de Bono; H I Scher
Journal:  Prostate Cancer Prostatic Dis       Date:  2013-10-01       Impact factor: 5.554

View more
  6 in total

1.  Therapeutic efficacy of 225Ac-PSMA-617 targeted alpha therapy in patients of metastatic castrate resistant prostate cancer after taxane-based chemotherapy.

Authors:  Ishita Sen; Parul Thakral; Priya Tiwari; Vineet Pant; Subha Shankar Das; Divya Manda; Vinod Raina
Journal:  Ann Nucl Med       Date:  2021-05-31       Impact factor: 2.668

2.  Using health insurance claims data to assess long-term disease progression in a prostate cancer cohort.

Authors:  Saira Khan; Sanah Vohra; Laura Farnan; Shekinah N C Elmore; Khadijah Toumbou; Madhav K C; Elizabeth T H Fontham; Edward S Peters; James L Mohler; Jeannette T Bensen
Journal:  Prostate       Date:  2022-07-26       Impact factor: 4.012

3.  Identification and Validation of the Prognostic Impact of Metastatic Prostate Cancer Phenotypes.

Authors:  Shelby A Labe; Xi Wang; Eric J Lehrer; Amar U Kishan; Daniel E Spratt; Christine Lin; Alicia K Morgans; Lee Ponsky; Jorge A Garcia; Sara Garrett; Ming Wang; Nicholas G Zaorsky
Journal:  Clin Genitourin Cancer       Date:  2022-02-24       Impact factor: 3.121

4.  Three-month early change in prostate-specific antigen levels as a predictive marker for overall survival during hormonal therapy for metastatic hormone-sensitive prostate cancer.

Authors:  Shotaro Nakanishi; Masato Goya; Mitsuyoshi Tamaki; Takuma Oshiro; Seiichi Saito
Journal:  BMC Res Notes       Date:  2021-06-03

5.  PSMA-11-PET/CT versus choline-PET/CT to guide stereotactic ablative radiotherapy for androgen deprivation therapy deferral in patients with oligometastatic prostate cancer.

Authors:  Charlotte L Deijen; Gerbert L Vrijenhoek; Eva E Schaake; Wouter V Vogel; Luc M F Moonen; Floris J Pos; Henk G van der Poel; Gerben R Borst
Journal:  Clin Transl Radiat Oncol       Date:  2021-06-29

6.  Pretreatment neutrophil-to-lymphocyte ratio as a potential prognostic biomarker for newly diagnosed patients with metastatic castration-sensitive prostate cancer.

Authors:  Samer Salah; Ramiz Abu-Hijlih; Fawzi Abuhijla; Faris Tamimi; Abdallah Al-Tell; Mohammed Shahait
Journal:  Cancer Rep (Hoboken)       Date:  2021-06-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.